Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design

• Главные авторы: Annunziata D'Ercole (Автор), Silvia Nistri (Автор), Lorenzo Pacini (Автор), Alfonso Carotenuto (Автор), Federica Santoro (Автор), Anna Maria Papini (Автор), Ross A. D. Bathgate (Автор), Daniele Bani (Автор), Paolo Rovero (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

The peptide hormone relaxin (RLX), also available as clinical-grade recombinant protein (serelaxin), holds great promise as a cardiovascular and anti-fibrotic agent but is limited by the pharmacokinetic issues common to all peptide drugs. In this study, by a computational modelling chemistry approac...